Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 8.59% is 22% below its 5-year average of 11.04%, around the middle of its 5-year range (-6.26%–35.49%).
10.89% below its 12-month average of 9.64%.
Reported quarterly profit margin; no daily interpolation. Q3 FY2026 (2026-06-30): 7.77%.
NET PROFIT MARGIN
8.59%
NET PROFIT MARGIN AVG TTM
9.64%
NET PROFIT MARGIN AVG 3Y
7.10%
NET PROFIT MARGIN AVG 5Y
11.04%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-10.89%
CURRENT VS 3Y AVG
+21.05%
CURRENT VS 5Y AVG
-22.16%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 699 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Market Cap
$355.41M
Net Profit Margin
-96.89%
TTM Avg
-148.47%
3Y Avg
-151.80%
5Y Avg
-119.69%
Market Cap
$353.62M
Net Profit Margin
-5.49%
TTM Avg
-11.37%
3Y Avg
-410.78%
5Y Avg
-2049.25%
Market Cap
$354.21M
Net Profit Margin
0.00%
TTM Avg
-11651.99%
3Y Avg
-6142.69%
5Y Avg
-4693.07%
Market Cap
$353.90M
Net Profit Margin
-184.60%
TTM Avg
-1235.34%
3Y Avg
-1300.41%
5Y Avg
-438.85%
Market Cap
$359.46M
Net Profit Margin
-1786.27%
TTM Avg
-1435.22%
3Y Avg
-1851.09%
5Y Avg
-9692.20%
Market Cap
$366.03M
Net Profit Margin
-1091.82%
TTM Avg
-436.37%
3Y Avg
-220.06%
5Y Avg
-1750.93%
Market Cap
$338.34M
Net Profit Margin
69.34%
TTM Avg
-109.76%
3Y Avg
-150.31%
5Y Avg
-135.75%
Market Cap
$374.66M
Net Profit Margin
-81.04%
TTM Avg
-157.37%
3Y Avg
-379.90%
5Y Avg
-317.33%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Embecta Corp. (EMBC) | $356.19M | 8.59% | 9.64% | 7.10% | 11.04% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $355.41M | -96.89% | -148.47% | -151.80% | -119.69% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $353.62M | -5.49% | -11.37% | -410.78% | -2049.25% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $354.21M | 0.00% | -11651.99% | -6142.69% | -4693.07% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $353.90M | -184.60% | -1235.34% | -1300.41% | -438.85% |
| Ocugen, Inc. (OCGN)vs › | $359.46M | -1786.27% | -1435.22% | -1851.09% | -9692.20% |
| Opus Genetics, Inc. (IRD)vs › | $366.03M | -1091.82% | -436.37% | -220.06% | -1750.93% |
| Agenus Inc. (AGEN)vs › | $338.34M | 69.34% | -109.76% | -150.31% | -135.75% |
| Canopy Growth Corporation (CGC)vs › | $374.66M | -81.04% | -157.37% | -379.90% | -317.33% |
| Cabaletta Bio, Inc. (CABA)vs › | $331.82M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
24.9%
Net Profit Margin
8.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 7.77% |
| 2026-03-31 | -1.85% |
| 2025-12-31 | 16.88% |
| 2025-09-30 | 10.00% |
| 2025-06-30 | 15.40% |
| 2025-03-31 | 9.07% |
| 2024-12-31 | -0.27% |
| 2024-09-30 | 5.10% |
| 2024-06-30 | 5.39% |
| 2024-03-31 | 10.06% |
| 2023-12-31 | 7.25% |
| 2023-09-30 | 2.13% |
| 2023-06-30 | 5.31% |
| 2023-03-31 | 5.05% |
| 2022-12-31 | 12.77% |
| 2022-09-30 | -6.26% |
| 2022-06-30 | 21.44% |
| 2022-03-31 | 29.00% |
| 2021-12-31 | 34.15% |
| 2021-09-30 | 32.31% |
| 2021-06-30 | 35.49% |
| 2021-03-31 | 37.97% |
| 2020-12-31 | 36.91% |
